Biocon Reaches Global Patent Settlement With Genentech for Pebrilzo
Biocon said it entered a global settlement and license agreement with Genentech for Pebrilzo, its biosimilar to Perjeta. The agreement resolves pending disputes between the companies.
Biocon Ltd on Wednesday said it has entered into a global settlement and license agreement with Genentech for breast cancer drug Pebrilzo, its biosimilar to the reference product Perjeta (Pertuzumab).The patent settlement agreement resolves all pending disputes between the two companies across mult…